Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medistim ASALTS:0OCD 97 EV-to-OCF is 24.27 as of Sep. 01, 2026, which is 26% below its 10-year median of 32.77. GuruFocus rates LTS:0OCD with a GF Score™ of 97/100 and a GF Value™ of kr263.26 (Fairly Valued). The stock has 4 warning signs investors should review. Among 851 Medical Devices & Instruments companies, Medistim ASA ranks worse than 80.38% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Medistim ASA's Enterprise Value is kr4,615.1 Mil.
Medistim ASA's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was kr190.1 Mil. Therefore, Medistim ASA's EV-to-OCF for today is 24.27.
The historical rank and industry rank for Medistim ASA's EV-to-OCF or its related term are showing as below:
LTS:0OCD'
s EV-to-OCF Range Over the Past 10 Years
Min: 16.4 Med: 32.77 Max: 94.76
Current: 24.46
During the past 13 years, the highest EV-to-OCF of Medistim ASA was 94.76. The lowest was 16.40. And the median was 32.77.
LTS:0OCD's EV-to-OCF is ranked worse than 80.38% of 851
companies
in the Medical Devices & Instruments industry
Industry Median: 7.83
vs LTS:0OCD: 24.46
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Medistim ASA's PE Ratio (TTM) for today is calculated as:
Medistim ASA's share price for today is kr259.00.
Medistim ASA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr9.030.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Medistim ASA EV-to-OCF Related Terms
Medistim ASA EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Medistim ASA's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Medistim ASA's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medistim ASA EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medistim ASA's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Medistim ASA's EV-to-OCF falls into.
Medistim ASA's current Enterprise Value is kr4,615.1 Mil.
Medistim ASA's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr190.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medistim ASA (LTS:0OCD) has a EV-to-OCF of 24.27 as of Sep. 01, 2026. This is 26% below median its historical median of 32.77. Over the past decade, Medistim ASA's EV-to-OCF has ranged from 16.40 to 94.76. According to the industry distribution chart, Medistim ASA ranks #684 out of 851 companies in the Medical Devices & Instruments industry, placing it in the top 80.4%.
Is Medistim ASA's EV-to-OCF too high?
Medistim ASA's current EV-to-OCF of 24.27 is 26% below median its 10-year median of 32.77. Over the past 10 years, this metric has ranged from a low of 16.40 to a high of 94.76. The Medical Devices & Instruments industry median EV-to-OCF is 7.83. Medistim ASA's value of 24.27 is 210% above this industry median. Based on the distribution chart, Medistim ASA ranks #684 out of 851 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Medistim ASA has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medistim ASA's EV-to-OCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medistim ASA ranks #684 out of 851 companies for EV-to-OCF. This places Medistim ASA in the lower half of its industry. The industry median EV-to-OCF is 7.83. Medistim ASA's value of 24.27 is 210% above this benchmark. Historically, Medistim ASA's own EV-to-OCF has ranged from 16.40 to 94.76 over the past decade. While the company's 10-year median is 32.77 vs. the industry median of 7.83, Medistim ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.83, based on 851 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medistim ASA's current EV-to-OCF of 24.27 is 210% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medistim ASA's current EV-to-OCF is 24.27, which is 26% below median its own 10-year median of 32.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medistim ASA stock overvalued right now?
Based on GuruFocus' analysis, Medistim ASA (LTS:0OCD) is currently considered Fairly Valued. The stock's GF Value™ is kr263.26, compared to a current price of kr259.00 — trading 1.6% below its estimated fair value. The current EV-to-OCF is 24.27, which is 26% below median its 10-year median of 32.77 and 210% above the Medical Devices & Instruments industry median of 7.83. Medistim ASA's overall GF Score™ is 97/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Medistim ASA (LTS:0OCD), the current EV-to-OCF is 24.27 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medistim ASA (LTS:0OCD) Overvalued in 2026?
Based on GuruFocus' analysis, Medistim ASA stock appears to be undervalued.
The current stock price of kr259.00 is trading 1.6% below its estimated GF Value™ of kr263.26.
GuruFocus considers Medistim ASA to be Fairly Valued.
Key valuation signals for LTS:0OCD:
EV-to-OCF: 24.27 (26% below median its 10-year median of 32.77)
GF Value™: kr263.26 vs. price of kr259.00 (1.6% below fair value)
Industry Position: 210% above the Medical Devices & Instruments median (#684 of 851)
No single metric tells the full story. See the LTS:0OCD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medistim ASA is a medical device company. It is engaged in researching, developing, producing, distributing, and sales of medical equipment through its own business or participation in other companies, as well as related activities. The company's business is focused on cardiac and vascular surgery. The group operates in the USA, Europe, China, and the Rest of the World. The main divisions are sale of own products and sale of third-party products. Sale of own products has two business models, the capital model and the lease model. Third-party products segment sells medical devices from third party manufacturers in Norway, Sweden and Denmark. Key revenue is generated from Own Products segment.
97GF Score
Get the complete analysis for LTS:0OCD
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0OCD has been successfully added to your 
